2023 연구성과 (7 / 285)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
WoS SCOPUS Document Type Document Title Abstract Authors Affiliation ResearcherID (WoS) AuthorsID (SCOPUS) Author Email(s) Journal Name JCR Abbreviation ISSN eISSN Volume Issue WoS Edition WoS Category JCR Year IF JCR (%) FWCI ⓘ FWCI Update Date WoS Citation SCOPUS Citation Keywords (WoS) KeywordsPlus (WoS) Keywords (SCOPUS) KeywordsPlus (SCOPUS) Language Publication Stage Publication Year Publication Date DOI JCR Link DOI Link WOS Link SCOPUS Link
○ Meeting Abstract ⓘ Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study) ⓘ ⓘ Lee, Ji Hyun; Min, Chang-Ki; Jo, Jae-Cheol; Lee, Yoo Jin; Kim, Jin Seok; Uhm, Hyun-Seok; Jung, Jong Heon; Moon, Joon Ho; Cho, Hee Jeong; Lee, Myung-won; Yoon, Sung-Soo; Byun, Ja Min; Lee, Jae Hoon; Lee, Je-Jung; Jung, Sung-Hoon; Shin, Ho-Jin; Kim, Do Young; Yi, Jun Ho; Lee, Seung-Shin; Do, Young Rok; Yoon, Dok Hyun; Cho, Hyungwoo; Lee, Won-Sik; Lee, Ho Sup; Uhm, Jieun; Kim, Hyo Jung; Jang, Hee Ryeong; Kim, Sung-Hyun; Kim, Kihyun ⓘ Dong A Univ, Coll Med, Busan, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Catholic Hematol Hosp, Coll Med,Dept Hematol, Seoul, South Korea; Ulsan Univ Hosp, Ulsan, South Korea; Univ Ulsan, Ulsan Univ Hosp, Coll Med, Ulsan, South Korea; Yonsei Univ, Severance Hosp, Coll Med, Dept Internal Med,Div Hematol, Seoul, South Korea; Natl Canc Ctr, Goyang, South Korea; Kyungpook Natl Univ Hosp, Daegu, South Korea; Chungnam Natl Univ Hosp, Daejeon, South Korea; Seoul Natl Univ Hosp, Dept Hematooncol, Seoul, South Korea; Seoul Natl Univ, Seoul, South Korea; Gachon Univ, Gil Med Ctr, Incheon, South Korea; Chonnam Natl Univ, Hwasun Hosp, Dept Hematol Oncol, Hwasun, South Korea; Chonnam Natl Univ, Med Sch, Hwasun, South Korea; Pusan Natl Univ Hosp, Dept Internal Med, Busan, South Korea; Pusan Natl Univ Hosp, Busan, South Korea; Chung Ang Univ, Seoul, South Korea; Wonkwang Univ Hosp, Iksan, South Korea; Keimyung Univ, Dongsan Med Ctr, Daegu, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea; Asan Med Ctr, Seoul, South Korea; Inje Univ, Busan Paik Hosp, Busan, South Korea; Kosin Univ, Coll Med, Busan, South Korea; Hanyang Univ, Coll Med, Seoul, South Korea; Hallym Univ, Coll Med, Anyang, South Korea; Kangwon Natl Univ Hosp, Chunchon, South Korea; Dong A Univ Hosp, Busan, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea ⓘ Uhm, Jieun/KQU-5990-2024; Jo, Jae-Cheol/CAE-9453-2022; KIM, JIN/I-6927-2019; Kim, Kihyun/D-5175-2013; Yi, Jun Ho/GXZ-8144-2022; Lee, Jong-Seok/J-5603-2012 ⓘ ⓘ ⓘ BLOOD ⓘ BLOOD ⓘ 0006-4971 1528-0020 142 SCIE HEMATOLOGY ⓘ 2023 21.1 1.5 ⓘ 0 ⓘ ⓘ ⓘ ⓘ English 2023 2023-11-02 10.1182/blood-2023-174439 ⓘ 바로가기 바로가기 바로가기
○ Meeting Abstract ⓘ Combinatorial Optimization of Chemotherapeutic Agents on T-Cell Acute Lymphoblastic Leukemia ⓘ ⓘ Kim, Juhyung; Hong Duc Nguyen Thi; Minh Tan Le; Cho, Hee Jeong; Moon, Joon Ho; Sohn, Sang Kyun; Baek, Dong Won ⓘ Kyungpook Natl Univ Hosp, Dept Hematol, Daegu, South Korea; Kyungpook Natl Univ, Grad Sch, Dept Biomed Sci, Daegu, South Korea; Kyungpook Natl Univ Hosp, Daegu, South Korea ⓘ ⓘ ⓘ ⓘ BLOOD ⓘ BLOOD ⓘ 0006-4971 1528-0020 142 SCIE HEMATOLOGY ⓘ 2023 21.1 1.5 ⓘ 0 ⓘ ⓘ ⓘ ⓘ English 2023 2023-11-02 10.1182/blood-2023-188246 ⓘ 바로가기 바로가기 바로가기
○ Meeting Abstract ⓘ Comparison of etoposide/cisplatin and irinotecan/cisplatin for extensive-stage small cell lung cancer in Koreans: A real-world retrospective observational study ⓘ ⓘ Lee, E.; Yoo, S. S.; Choi, S. H.; Seo, H.; Lee, S. Y.; Cha, S. I.; Kim, C. H.; Park, J. Y. ⓘ Kyungpook Natl Univ, Chilgok Hosp, Thorac Surg, Daegu, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Dept Internal Med, Daegu, South Korea; Kyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea ⓘ Park, Sun/ABB-2937-2021 ⓘ ⓘ ⓘ JOURNAL OF THORACIC ONCOLOGY ⓘ J THORAC ONCOL ⓘ 1556-0864 1556-1380 18 4 SCIE ONCOLOGY;RESPIRATORY SYSTEM ⓘ 2023 21.1 1.5 ⓘ 0 ⓘ ⓘ ⓘ ⓘ English 2023 2023-04 ⓘ 바로가기 바로가기
○ ○ Article ⓘ Comparison of methods for estimating basal endogenous losses of amino acids and additivity of digestibility of amino acids in corn and soybean meal for broilers ⓘ This study was to compare the estimates of basal endogenous losses (BEL) of amino acids (AA) determined by 3 methods including feeding a nitrogen-free diet (NFD) or a low-casein diet (LCD, containing casein at 30 g/kg diet) or using the regression method. Another objective was to investigate whether the ileal AA digestibility of corn calculated from a casein-supplemented corn diet is additive for a corn soybean meal (SBM) mixed diet in broilers. On d 31 of age, 168 Ross 308 male broilers were assigned to 8 dietary treatments with 6 replicates in a randomized complete block design. An NFD and 3 diets containing 30, 60, or 90 g/kg of casein were formulated to determine the BEL of AA and ileal AA digestibility of casein. The other 4 diets consisted of a corn diet, SBM diet, casein-supplemented corn diet, and corn-SBM mixed diet. On d 35 of age, digesta from the distal section of the ileum were collected. The BEL of AA in birds fed the LCD were greater (P < 0.05) than those of the NFD and the regression method. There were no differences in the BEL of AA determined between the NFD and the regression method. Apparent ileal digestibility (AID) and standardized ileal digestibility (SID) of AA for corn calculated from the casein-supplemented corn diet were greater (P < 0.05) than those of the corn diet. The predicted AID of Thr in the corn-SBM mixed diet based on the AID of AA for corn in the corn diet was lower (P < 0.05) than the measured AID. However, the predicted AID of AA in the mixed diet based on the AID of AA for corn in the casein-supplemented corn diet did not differ from the measured AID. The predicted SID of AA in the mixed diet did not differ from the measured SID irrespective of casein supplementation. In conclusion, feeding an NFD or using the regression method yields similar BEL of AA, but not feeding an LCD. Casein supplementation in the corn diet increases the ileal AA digestibility for corn, which is additive for the corn-SBM mixed diet.(c) 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. ⓘ Yoon, June Hyeok; Kong, Changsu ⓘ Kyungpook Natl Univ, Dept Anim Sci & Biotechnol, Sangju 37224, Gyeongsangbug, South Korea; Kyungpook Natl Univ, Dept Anim Sci, Sangju 37224, South Korea; Kyungpook Natl Univ, Res Inst Horse Ind, Sangju 37224, South Korea ⓘ ⓘ 57995779900; 36027521600 ⓘ changsukong@knu.ac.kr; ⓘ ANIMAL NUTRITION ⓘ ANIM NUTR ⓘ 2405-6383 2405-6545 15 SCIE AGRICULTURE, DAIRY & ANIMAL SCIENCE;VETERINARY SCIENCES ⓘ 2023 6.1 1.5 0.6 2025-06-25 ⓘ 2 2 Amino acid; Casein; Broiler; Additivity; Basal endogenous loss ⓘ FEED INGREDIENTS; FREE DIETS; FLOW; CHICKENS; APPARENT; CASEIN; ENERGY; SWINE; AGE ⓘ Additivity; Amino acid; Basal endogenous loss; Broiler; Casein ⓘ alanine; amino acid; arginine; aspartic acid; cysteine; glutamic acid; glycine; histidine; isoleucine; lysine; methionine; phenylalanine; proline; serine; threonine; tyrosine; valine; animal experiment; animal food; Article; broiler; chemical analysis; controlled study; digestion; intermethod comparison; low casein diet; maize; male; nitrogen free diet; nonhuman; soybean meal ⓘ English 2023 2023-12 10.1016/j.aninu.2023.07.002 ⓘ 바로가기 바로가기 바로가기 바로가기
○ Meeting Abstract ⓘ Concordance Between Generative AI GPT-4 and NCCN Guidelines: Biomarker-Driven Treatment Strategies in NSCLC ⓘ ⓘ Kim, H. S.; Lee, J.; Chae, Y. K. ⓘ Northwestern Univ, Feinberg Sch Med, Chicago, IL USA; Kyungpook Natl Univ, Sch Med, Daegu, South Korea ⓘ ⓘ ⓘ ⓘ JOURNAL OF THORACIC ONCOLOGY ⓘ J THORAC ONCOL ⓘ 1556-0864 1556-1380 18 11 SCIE ONCOLOGY;RESPIRATORY SYSTEM ⓘ 2023 21.1 1.5 ⓘ 0 Artificial intelligence; Biomarker; NCCN guidelines ⓘ ⓘ ⓘ ⓘ English 2023 2023-11 ⓘ 바로가기 바로가기
○ Article ⓘ Digital-Twin Consistency Checking Based on Observed Timed Events With Unobservable Transitions in Smart Manufacturing ⓘ Smart factories manage digital twins (DTs) to evaluate the performance of various what-if production scenarios. This article presents a DT consistency-checking approach to maintain DT in high fidelity by checking whether each sensed timed event from the physical manufacturing plant is under its corresponding DT-based estimations in runtime. The approach targets DTs developed using time colored Petri net (TCPN). To build the candidates of the next observable event with observable time margins, we considered the stochastic property of the plant, frequent external actuation caused by a new order, machine maintenance, etc., as well as intermediate unobservable state transitions reaching the sensible events. Based on the considerations, we propose an iterative method to build the virtual estimates for streaming physical events using efficiently evolved state-class graphs (SCGs). We also propose a TCPN partitioning method to accelerate the SCG-evolution and make DT maintenance easier by supporting the isolation of inconsistent subnets being diagnosed. We applied the approach to a USB flash-drive factory to prove the concept and evaluated the performance under various situations to show speedups of the SCG evolution, that is the crucial overhead of the estimation. © 2005-2012 IEEE. ⓘ Seok, Moon Gi; Tan, Wen Jun; Cai, Wentong; Park, Daejin ⓘ Nanyang Technological University, School of Computer Science and Engineering, Singapore, 639798, Singapore; Nanyang Technological University, School of Computer Science and Engineering, Singapore, 639798, Singapore; Nanyang Technological University, School of Computer Science and Engineering, Singapore, 639798, Singapore; Kyungpook National University (KNU), School of Electronics Engineering, Daegu, 702-701, South Korea ⓘ ⓘ 36683242700; 55445115300; 7401711207; 55463943600 ⓘ boltanut@knu.ac.kr; ⓘ IEEE Transactions on Industrial Informatics ⓘ IEEE T IND INFORM ⓘ 1551-3203 1941-0050 19 4 SCIE AUTOMATION & CONTROL SYSTEMS;COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS;ENGINEERING, INDUSTRIAL ⓘ 2023 11.7 1.5 1.27 2025-06-25 ⓘ 11 ⓘ ⓘ Digital twin (DT); manufacturing system; reachability analysis; state-class graph (SCG); time petri net (TPN) ⓘ Flow control; Iterative methods; Manufacture; Monitoring; Petri nets; Stochastic systems; Consistency checking; Informatics; Manufacturing; Performance; Reachability analysis; Runtimes; Smart manufacturing; State class graph; Time coloreds; Time Petri nets; Random processes ⓘ English Final 2023 10.1109/tii.2022.3200598 ⓘ 바로가기 바로가기 바로가기
○ ○ Article ⓘ Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum ⓘ BackgroundNeuromyelitis optica spectrum disorder (NMOSD) causes relapsing inflammatory attacks in the central nervous system, leading to disability. As rituximab, a B-lymphocyte-depleting monoclonal antibody, is an effective in preventing NMOSD relapses, we hypothesised that earlier initiation of rituximab can also reduce long-term disability of patients with NMOSD. MethodsThis multicentre retrospective study involving 19 South Korean referral centres included patients with NMOSD with aquaporin-4 antibodies receiving rituximab treatment. Factors associated with the long-term Expanded Disability Status Scale (EDSS) were assessed using multivariable regression analysis. ResultsIn total, 145 patients with rituximab treatment (mean age of onset, 39.5 years; 88.3% female; 98.6% on immunosuppressants/oral steroids before rituximab treatment; mean disease duration of 121 months) were included. Multivariable analysis revealed that the EDSS at the last follow-up was associated with time to rituximab initiation (interval from first symptom onset to initiation of rituximab treatment). EDSS at the last follow-up was also associated with maximum EDSS before rituximab treatment. In subgroup analysis, the time to initiation of rituximab was associated with EDSS at last follow-up in patients aged less than 50 years, female and those with a maximum EDSS score >= 6 before rituximab treatment. ConclusionsEarlier initiation of rituximab treatment may prevent long-term disability worsening in patients with NMOSD, especially among those with early to middle-age onset, female sex and severe attacks. ⓘ Park, Su Yeon; Kwon, Young Nam; Kim, Sunyoung; Kim, Seung-Hyun; Kim, Jong Kuk; Kim, Jun-Soon; Nam, Tai-Seung; Min, Young Gi; Park, Kyung Seok; Park, Jin-Sung; Seok, Jin Myoung; Sung, Jung-Joon; Sohn, Eunhee; Shin, Kyong Jin; Shin, Jin-Hong; Shin, Ha Young; Oh, Seong-il; Oh, Jeeyoung; Yoon, Byeol-A; Lee, Sanggon; Lee, Jong-Mok; Lee, Hye Lim; Choi, Kyomin; Huh, So-Young; Jang, Myoung-jin; Min, Ju-Hong; Kim, Byoung Joon; Kim, Sung-Min ⓘ Korea Canc Ctr Hosp, Dept Neurol, Seoul, South Korea; Seoul Natl Univ Hosp, Biomed Res Inst, Dept Neurol, Seoul, South Korea; Ulsan Univ Hosp, Dept Neurol, Coll Med, Ulsan, South Korea; Hanyang Univ, Dept Neurol, Coll Med, Seoul, South Korea; Dong A Univ, Dept Neurol, Coll Med, Pusan, South Korea; Seoul Natl Univ, Dept Neurol, Bundang Hosp, Seongnam, South Korea; Chonnam Natl Univ, Chonnam Natl Univ Hosp, Dept Neurol, Med Sch, Gwangju, South Korea; Seoul Natl Univ, Dept Neurol, Coll Med, Seoul, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Chilgok Hosp, Sch Med, Dept Neurol, Daegu, South Korea; Soonchunhyang Univ, Coll Med, Dept Neurol, Cheonan Hosp, Cheonan, South Korea; Chungnam Natl Univ, Coll Med, Dept Neurol, Daejeon, South Korea; Inje Univ, Haeundae Paik Hosp, Dept Neurol, Pusan, South Korea; Pusan Natl Univ, Dept Neurol, Yangsan Hosp, Yangsan, South Korea; Yonsei Univ, Dept Neurol, Coll Med, Seoul, South Korea; Inje Univ, Busan Paik Hosp, Dept Neurol, Coll Med, Busan, South Korea; Konkuk Univ, Dept Neurol, Sch Med, Seoul, South Korea; Chung Ang Univ, Dept Neurol, Gwangmyeong Hosp, Gwangmyeong, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Neurol, Daegu, South Korea; Korea Univ, Dept Neurol, Coll Med, Seoul, South Korea; Kosin Univ, Dept Neurol, Coll Med, Pusan, South Korea; Seoul Natl Univ Hosp, Med Res Collaborating Ctr, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Neurol, Sch Med, Seoul, South Korea; Seoul Natl Univ, Dept Neurol, Coll Med, Seoul 03080, South Korea ⓘ Kim, Tae/B-9921-2013; Lee, Jong-Mok/KVY-9550-2024; Park, Kyung/J-5472-2012; Kuk, Kim/ABH-5221-2020; Shin, Jin-Hong/AAZ-8809-2020; lee, wj/JNR-4926-2023; KIM, Seung Hyun/T-5133-2017; Oh, Seong-il/A-8790-2019 ⓘ 54893217600; 57211139914; 57196226825; 55911799500; 54580955800; 57196479070; 35170886500; 57210822357; 35332775700; 44061744500; 57197061814; 7402627011; 35890331200; 55675483300; 36538204000; 7404012350; 47861459800; 57193861769; 57141756000; 57219600016; 57192075673; 57202973906; 56274242700; 55629102100; 55317673900; 8235117900; 57210179291; 57837876800 ⓘ bjkim@skku.edu;sueh916@gmail.com; ⓘ JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY ⓘ J NEUROL NEUROSUR PS ⓘ 0022-3050 1468-330X 94 10 SCIE CLINICAL NEUROLOGY;PSYCHIATRY;SURGERY ⓘ 2023 8.8 1.5 2.38 2025-06-25 ⓘ 11 10 NEUROIMMUNOLOGY ⓘ EFFICACY; DISORDERS; MULTICENTER; THERAPIES; RELAPSE; SAFETY ⓘ NEUROIMMUNOLOGY ⓘ Adult; Aquaporin 4; Aquaporins; Autoantibodies; Female; Humans; Male; Middle Aged; Neuromyelitis Optica; Retrospective Studies; Rituximab; aquaporin 4 antibody; immunosuppressive agent; rituximab; steroid; aquaporin; aquaporin 4; autoantibody; rituximab; adolescent; adult; aged; Article; child; clinical outcome; controlled study; disability; disease duration; early intervention; Expanded Disability Status Scale; female; follow up; gender; human; human cell; major clinical study; male; middle aged; multivariate logistic regression analysis; myelooptic neuropathy; neuroimmunology; onset age; retrospective study; South Korean; study design; time to treatment; clinical trial; multicenter study; myelooptic neuropathy ⓘ English 2023 2023-10 10.1136/jnnp-2022-330714 ⓘ 바로가기 바로가기 바로가기 바로가기
○ Meeting Abstract ⓘ EGFR Exon 20 Insertion Mutations in NSCLC: The Need for Accurate Naming Conventions and Implications for Personalized Therapy ⓘ ⓘ Park, J.; Song, J. -Y.; Sung, M.; Kwon, M. J.; Kim, C. R.; Shin, Y. K.; Choi, Y. -L. ⓘ Seoul Natl Univ, Seoul, South Korea; Samsung Med Ctr, Seoul, South Korea; Sungkyunkwan Univ, Seoul, South Korea; Kyungpook Natl Univ, Daegu, South Korea ⓘ ⓘ ⓘ ⓘ JOURNAL OF THORACIC ONCOLOGY ⓘ J THORAC ONCOL ⓘ 1556-0864 1556-1380 18 11 SCIE ONCOLOGY;RESPIRATORY SYSTEM ⓘ 2023 21.1 1.5 ⓘ 0 EGFR exon20 insertion; HGVS nomenclature; Detection methods ⓘ ⓘ ⓘ ⓘ English 2023 2023-11 ⓘ 바로가기 바로가기
○ ○ Article ⓘ Experimental and numerical investigation on a solar-driven torrefaction reactor using woody waste (Ashe Juniper) ⓘ In this work, designs a novel solar-driven thermochemical conversion reactor to torrefy biomass waste (Ashe Juniper) for further pyrolysis applications. The effect of torrefaction temperature and residence time on the properties of biomass waste was investigated and results showed that torrefaction temperature dominates the properties of product compared to the effect of residence time. The highest energy yield (over 90%) was obtained at 210 degrees C while the highest energy densification (-1.51) was achieved at 360 degrees C. In addition, a two-step kinetic numerical model was used to analyze and predict the experimental process (kinetic rates) and results (C, H, and O contents) based on the experimental results. The analysis results showed that the predicted results are in good agreement with the practical results after torrefaction, indicating the feasibility of this numerical model for torrefaction and pyrolysis applications. The carbon footprint analysis showed that reduction effect of 1.3 -1.6 tCO2/ton-AJ can be obtained by torrefaction of Ashe Juniper. Finally, the prospects for future industrial appli-cations of solar-driven torrefaction reactors discussed as one of affordable and clean energy. ⓘ Rodriguez-Alejandro, David Aaron; Nam, Hoseok; Granados-Lieberman, David; Wang, Shuang; Hwang, Sung-Chul; Nam, Hyungseok; Capareda, Sergio C. ⓘ Univ Guanajuato, Salamanca 36885, Gto, Mexico; Texas A&M Univ, College Stn, TX 77843 USA; Busan Res Inst, Pusan 47210, South Korea; Natl Technol Inst Mexico, Irapuato 36821, Gto, Mexico; Kyungpook Natl Univ, Daegu 41566, South Korea; GET SCR Co Ltd, R&D Ctr, Mryang 50404, South Korea ⓘ ; Nam, Hoseok/MTF-8047-2025; RODRIGUEZ-ALEJANDRO, DAVID/JHU-0787-2023; Capareda, Sergio/C-5843-2015 ⓘ 57163753900; 57198350465; 35095154600; 57216215741; 57191483720; 57190418228; 8656086100 ⓘ namhs219@knu.ac.kr; ⓘ ENERGY CONVERSION AND MANAGEMENT ⓘ ENERG CONVERS MANAGE ⓘ 0196-8904 1879-2227 288 SCIE ENERGY & FUELS;MECHANICS;THERMODYNAMICS ⓘ 2023 9.9 1.5 1.59 2025-06-25 ⓘ 12 15 Solar Energy; Torrefaction; Pyrolysis; Ashe Juniper; Biochar; Carbon Analysis ⓘ INDUSTRIAL-PROCESS HEAT; ACTIVATED CARBON; PHYSICOCHEMICAL PROPERTIES; PYROLYSIS; BIOCHAR; SEQUESTRATION; TEMPERATURE; KINETICS ⓘ Ashe Juniper; Biochar; Carbon Analysis; Pyrolysis; Solar Energy; Torrefaction ⓘ Carbon footprint; Numerical models; Pyrolysis; Ashe juniper; Biochar; Biomass wastes; Carbon analysis; Experimental investigations; Numerical investigations; Property; Residence time; Torrefaction; Work design; Solar energy ⓘ English 2023 2023-07-15 10.1016/j.enconman.2023.117114 ⓘ 바로가기 바로가기 바로가기 바로가기
○ Meeting Abstract ⓘ Incidence and Survival Outcomes of Lung Cancer Post-Double Lung Transplant and its Association with Graft Rejection ⓘ ⓘ Kim, H. S.; Lee, J.; Chung, L. I. -Y.; Yu, J.; Bharat, A.; Chae, Y. K. ⓘ Northwestern Univ, Feinberg Sch Med, Chicago, IL USA; Kyungpook Natl Univ, Sch Med, Daegu, South Korea ⓘ Chung, Liam Il-Young/IQU-0821-2023 ⓘ ⓘ ⓘ JOURNAL OF THORACIC ONCOLOGY ⓘ J THORAC ONCOL ⓘ 1556-0864 1556-1380 18 11 SCIE ONCOLOGY;RESPIRATORY SYSTEM ⓘ 2023 21.1 1.5 ⓘ 0 Double lung transplantation; Post-transplant lung cancer; Graft rejection ⓘ ⓘ ⓘ ⓘ English 2023 2023-11 ⓘ 바로가기 바로가기
○ ○ Article ⓘ Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR ⓘ Introduction: This study aimed to investigate real-world evidence for efficacy and safety of durvalumab consolida-tion (DC) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC.Methods: Patients with stage III NSCLC who started DC after CRT between September 2018 and December 2020 and were treated at five tertiary hospitals in the Republic of Korea were included. The primary end point was real-world progression-free survival (rwPFS). Secondary end points were overall survival, objective response rate, and adverse events including radiation pneumonitis (RP) and immune-related adverse events (irAEs).Results: A total of 157 patients were enrolled. At the me-dian follow-up of 19.1 months, median rwPFS of DC was 25.9 months (95% confidence interval: 16.5-35.4) and the 1-, 2-, and 3-year rwPFS rates were 59.4%, 51.8%, and 43.5%, respectively. The median overall survival was not mature, and objective response rate of DC was 51.0%. High programmed death-ligand 1 expression (>50%) and development of RP requiring steroid treatment were significantly associated with longer (p = 0.043) and shorter rwPFS (p = 0.036), respectively. RP, RP requiring steroid treatment, and irAEs developed in 57 (36.3%), 42 (26.8%), and 53 (33.8%) patients, respectively. Among peripheral blood cell counts at the initiation of DC, a high derived monocyte-to-lymphocyte ratio was the most significant risk factor for the development of RP requiring steroid treatment (OR 44.76, 95% CI: 8.89-225.43, p < 0.001) and irAEs (OR 2.85, 95% CI: 1.27-6.41, p = 0.011).Conclusions: Compared with the outcome of the PACIFIC trial, these real-world data revealed favorable survival benefits of DC after CRT in patients with unresectable stage III NSCLC. Blood-based biomarkers could predict higher grade RP and irAEs before the initiation of DC.& COPY; 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/). ⓘ Park, Cheol-Kyu; Oh, Hyung-Joo; Kim, Young-Chul; Kim, Yong-Hyub; Ahn, Sung-Ja; Jeong, Won Gi; Lee, Jeong Yeop; Lee, Jae Cheol; Choi, Chang Min; Ji, Wonjun; Song, Si Yeol; Choi, Juwhan; Lee, Sung Yong; Kim, Hakyoung; Lee, Shin Yup; Park, Jongmoo; Yoon, Seong Hoon; Joo, Ji Hyeon; Oh, In-Jae ⓘ Chonnam Natl Univ, Med Sch, Dept Internal Med, 322 Seoyang Ro, Hwasun 58128, Jeonnam, South Korea; Hwasun Hosp, 322 Seoyang Ro, Hwasun 58128, Jeonnam, South Korea; Chonnam Natl Univ, Med Sch, Dept Radiat Oncol, Hwasun, Jeonnam, South Korea; Chonnam Natl Univ, Med Sch, Dept Radiol, Hwasun, Jeonnam, South Korea; Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea; Univ Ulsan, Asan Med Ctr, Dept Pulm & Crit Care Med, Coll Med, Seoul, South Korea; Univ Ulsan, Asan Med Ctr, Dept Radiat Oncol, Coll Med, Seoul, South Korea; Korea Univ, Guro Hosp, Dept Internal Med, Coll Med, Seoul, South Korea; Korea Univ, Coll Med, Dept Radiat Oncol, Guro Hosp, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Dept Radiat Oncol, Daegu, South Korea; Pusan Natl Univ, Yangsan Hosp, Dept Internal Med, Sch Med, Yangsan, Gyeongnam, South Korea; Pusan Natl Univ, Yangsan Hosp, Dept Radiat Oncol, Sch Med, Yangsan, Gyeongnam, South Korea ⓘ Oh, In-Jae/AAG-5919-2020; Lee, Sang-Jun/A-3892-2015; Lee, Joo Yong/ADE-2110-2022; Kim, Yong-Joo/AAK-1840-2021; Park, Cheol-Kyu/AAT-9872-2021 ⓘ 57205721111; 57216363864; 35201246200; 56488759800; 57211944596; 57218772158; 57375468600; 24825051600; 14024046800; 55256983400; 35278504200; 57193228530; 56734650000; 59324660000; 49863712700; 56180048900; 55479240500; 55888566300; 58754601500 ⓘ droij@jnu.ac.kr; ⓘ JOURNAL OF THORACIC ONCOLOGY ⓘ J THORAC ONCOL ⓘ 1556-0864 1556-1380 18 8 SCIE ONCOLOGY;RESPIRATORY SYSTEM ⓘ 2023 21.1 1.5 3.74 2025-06-25 ⓘ 21 23 Real-world data; Chemoradiotherapy; Durvalu-mab; Non-small cell lung cancer ⓘ LUNG-CANCER; RADIATION PNEUMONITIS; CONCURRENT CHEMORADIOTHERAPY; LYMPHOCYTE RATIO; SURVIVAL ⓘ Chemoradiotherapy; Durvalumab; Non–small cell lung cancer; Real-world data ⓘ Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Humans; Lung Neoplasms; Radiation Pneumonitis; Republic of Korea; Steroids; durvalumab; programmed death 1 ligand 1; steroid; durvalumab; steroid; adult; aged; Article; cancer patient; cancer staging; chemoradiotherapy; consolidation chemotherapy; drug efficacy; drug safety; female; human; inoperable cancer; Korean (people); major clinical study; male; monocyte lymphocyte ratio; non small cell lung cancer; observational study; overall survival; progression free survival; protein expression; radiation pneumonia; retrospective study; risk factor; steroid therapy; chemoradiotherapy; epidemiology; lung tumor; non small cell lung cancer; radiation pneumonia; South Korea ⓘ English 2023 2023-08 10.1016/j.jtho.2023.04.008 ⓘ 바로가기 바로가기 바로가기 바로가기
○ Meeting Abstract ⓘ Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy ⓘ ⓘ Oh, H. -J.; Park, C. -K.; Kim, Y. -C.; Kim, Y. -H.; Ahn, S. -J.; Jeong, W. G.; Lee, J. Y.; Lee, J. C.; Choi, C. M.; Ji, W.; Song, S. Y.; Choi, J.; Lee, S. Y.; Kim, H.; Lee, S. Y.; Park, J.; Yoon, S. H.; Joo, J. H.; Oh, I. -J. ⓘ Chonnam Natl Univ, Sch Med, Jeonnam, South Korea; Hwasun Hosp, Jeonnam, South Korea; Univ Ulsan, Coll Med, Asan Med Cenc, Seoul, South Korea; Korea Univ, Coll Med, Guro Hosp, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Daegu, South Korea; Pusan Natl Univ, Sch Med, Yangsan Hosp, Gyeongnam, South Korea ⓘ Kim, Seoyoung/L-6561-2019; Park, Cheol-Kyu/AAT-9872-2021 ⓘ ⓘ ⓘ JOURNAL OF THORACIC ONCOLOGY ⓘ J THORAC ONCOL ⓘ 1556-0864 1556-1380 18 11 SCIE ONCOLOGY;RESPIRATORY SYSTEM ⓘ 2023 21.1 1.5 ⓘ 1 real-world data; chemoradiotherapy; durvalumab ⓘ ⓘ ⓘ ⓘ English 2023 2023-11 ⓘ 바로가기 바로가기
○ Meeting Abstract ⓘ Multicenter, Prospective Study to Investigate the Efficacy and Safety of IntravenousImmunoglobulin Therapy in Elderly Patients with Diffuse Large B Cell Lymphoma Treated with R-Mini-CHOP ⓘ ⓘ Baek, Dong Won; Song, Ga-Young; Choi, Hyukjin; Lee, Ho Sup; Do, Young Rok; Lee, Ji Hyun; Moon, Joon Ho; Yang, Deok-Hwan ⓘ Kyungpook Natl Univ Hosp, Dept Hematol, Daegu, South Korea; Chonnam Natl Univ, Hwasun Hosp, Hwasun, South Korea; Kyungpook Natl Univ Hosp, Daegu, South Korea; Kosin Univ, Gospel Hosp, Busan, South Korea; Keimyung Univ, Dongsan Med Ctr, Daegu, South Korea; Dong A Univ, Coll Med, Busan, South Korea; Kyungpook Natl Univ Hosp, Dept Hematol Oncol, Seoul, South Korea; Chonnam Natl Univ, Dept Hematol Oncol, Hwasun Hosp, Hwasun, South Korea ⓘ ⓘ ⓘ ⓘ BLOOD ⓘ BLOOD ⓘ 0006-4971 1528-0020 142 SCIE HEMATOLOGY ⓘ 2023 21.1 1.5 ⓘ 0 ⓘ ⓘ ⓘ ⓘ English 2023 2023-11-02 10.1182/blood-2023-189114 ⓘ 바로가기 바로가기 바로가기
○ ○ Article ⓘ Standardized ileal digestible lysine requirements based on growth performance and histochemical characteristics of male broilers from 10 to 21 d of age ⓘ The growth performance and histochemical characteristics of breast muscle fibers were used to estimate the standardized ileal digestible (SID) Lys requirements for 10- to 21-d-old male broilers. Three hundred and sixty 10-d-old Ross 308 broilers (290 +/- 16.6 g) were allocated to 6 diets in a randomized complete block design with 6 replicate cages per treatment and 10 birds per cage. The 6 experimental diets were formulated to contain equally spaced increasing levels of SID Lys from 0.86% to 1.36%. The data were analyzed using the MIXED procedure of SAS. The Lys requirements were estimated by the NLIN procedure of SAS. An increase in dietary SID Lys from 0.86% to 1.36% resulted in a quadratic increase (P < 0.05) in body weight gain (BWG), gain to feed ratio (G:F), breast weight, muscle cross-sectional area (MCSA), and fiber area. The SID Lys requirements based on the one-slope broken-line, quadratic line, the first intercept between the plateau of the one-slope broken-line and quadratic-line models and 95% of the upper asymptote of the quadratic-line model were estimated to be 1.01%, 1.19%, 1.08%, and 1.13% for BWG, 1.06%, 1.22%, 1.11%, and 1.16% for G:F, 1.10%, 1.29%, 1.19%, and 1.22% for breast weight, 1.06%, 1.22%, 1.12%, and 1.16% for MCSA, and 1.14%, 1.22%, 1.16%, and 1.16% for breast muscle fiber area, respectively. It was concluded that the SID Lys requirements for broilers at the age of 10 to 21 d depended on the response variables used for estimation, and that histochemical characteristics of breast muscle fibers could be good indicators for estimating SID Lys requirements.(c) 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/). ⓘ An, Su Hyun; Lee, Boin; Choi, Young Min; Kong, Changsu ⓘ Kyungpook Natl Univ, Dept Anim Sci & Biotechnol, Sangju 37224, South Korea; Kyungpook Natl Univ, Dept Anim Sci, Sangju 37224, South Korea ⓘ 안, 수현/JFK-5079-2023 ⓘ 57216974969; 57218130871; 57226673843; 36027521600 ⓘ changsukong@knu.ac.kr; ⓘ ANIMAL NUTRITION ⓘ ANIM NUTR ⓘ 2405-6383 2405-6545 12 SCIE AGRICULTURE, DAIRY & ANIMAL SCIENCE;VETERINARY SCIENCES ⓘ 2023 6.1 1.5 1.2 2025-06-25 ⓘ 4 4 Requirement; Lysine; Growth performance; Muscle fiber characteristics; Broiler chicken ⓘ PECTORALIS MAJOR MUSCLE; AMINO-ACID RESPONSES; MEAT QUALITY; NUMBER ⓘ Broiler chicken; Growth performance; Lysine; Muscle fiber characteristics; Requirement ⓘ lysine; animal experiment; animal model; Article; body weight; body weight gain; bone density; broiler; chemical analysis; diet supplementation; experimental diet; gain to feed ratio; growth rate; histochemistry; image analysis; male; muscle cell; muscle growth; nonhuman; skeletal muscle cell ⓘ English 2023 2023-03 10.1016/j.aninu.2022.09.012 ⓘ 바로가기 바로가기 바로가기 바로가기
○ Meeting Abstract ⓘ The Co-Occurrence of bZIP in-Frame CEBPA-Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia ⓘ ⓘ Ahn, Jae-Sook; Kim, Mihee; Ahn, Seo-Yeon; Kim, Mi Yeon; Song, Ik Chan; Park, Yong; Cheong, June-Won; Yhim, Ho-Young; Do, Young Rok; Lee, Yoo Jin; Park, Seong Kyu; Bae, Sung Hwa; Shin, Ho-Jin; Lee, Hyewon; Han, Jae Joon; Kim, Min Kyoung; Lee, Ho Sup; Jung, Chul Won; Jang, Jun Ho; Moon, Joon Ho; Sohn, Sang Kyun; Won, Jong-Ho; Kim, Sung-Hyun; Kim, Dennis D. H.; Kim, Heeje; Kim, Hyeoung Joon ⓘ Chonnam Natl Univ, Hwasun Hosp, Dept Hematol Oncol, Hwasun, South Korea; Chonnam Natl Univ, Hwasun Hosp, Genom Res Ctr Hematopoiet Dis, Hawsun, Jeollanam Do, South Korea; Chonnam Natl Univ, Hwasun Hosp, Hematol Oncol, Hawsun, Jeollanam Do, South Korea; Chungnam Natl Univ, Coll Med, Dept Internal Med, Daejeon, South Korea; Korea Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Yonsei Univ, Coll Med, Seoul, South Korea; Jeonbuk Natl Univ, Dept Internal Med, Med Sch, Jeonju, South Korea; Keimyung Univ, Dongsan Med Ctr, Daegu, South Korea; Univ Ulsan, Coll Med, Ulsan Univ Hosp, Ulsan, South Korea; Soonchunhyang Univ, Bucheon Hosp, Dept Hematol ncol, Bucheon, South Korea; Daegu Catholic Univ, Daegu Catholic Univ Hosp, Sch Med, Dept Internal Med, Daegu, South Korea; Pusan Natl Univ Hosp, Busan, South Korea; Natl Canc Ctr, Goyang, South Korea; Kyung Hee Univ, Med Ctr, Seoul, South Korea; Yeungnam Univ Hosp, Daegu, South Korea; Kosin Univ, Gospel Hosp, Busan, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea; Samsung Med Ctr, Dept Internal Med, Div Hematol Oncol, Seoul, South Korea; Kyungpook Natl Univ Hosp, Daegu, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Daegu, South Korea; Soon Chun Hyang Univ Hosp, Coll Med, Seoul, South Korea; Dong A Univ Hosp, Busan, South Korea; Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Hematol, Seoul, South Korea ⓘ Kim, Chang Gon/IAP-6721-2023; Won, Jongho/AAM-8322-2021; Kim, Dennis/AAH-8499-2019; Lee, Sang-Jun/A-3892-2015; Kim, Min/ACN-6827-2022; Yhim, Ho-Young/J-1531-2012; Kim, Jungok/JWP-9097-2024; LEE, SEOK-YONG/A-8012-2012; Park, Jung Hyun/HJA-3755-2022; Hyun-Jung, Kim/E-8074-2011; ­, 한재준(의과대학 의학과)/AAT-6350-2020; Kim, Hyung Joon/ABD-3143-2020; Lee, Yoojin/AAB-9799-2022 ⓘ ⓘ ⓘ BLOOD ⓘ BLOOD ⓘ 0006-4971 1528-0020 142 SCIE HEMATOLOGY ⓘ 2023 21.1 1.5 ⓘ 0 ⓘ ⓘ ⓘ ⓘ English 2023 2023-11-02 10.1182/blood-2023-180499 ⓘ 바로가기 바로가기 바로가기
페이지 이동: